Evidence map›Paper›PMID 42041719›Full record

GuidelineCurrent oncology (Toronto, Ont.)2026

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, Jean-François Boileau, Nathaniel Bouganim, Christine Brezden-Masley, Jeffrey Q Cao, David W Cescon, Stephen Chia, Scott Edwards and 8 more

Abstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aalok KumarBC Cancer-Surrey, University of British Columbia, Vancouver, BC V3V 1Z2, Canada.
Katarzyna J JerzakSunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Karen A GelmonBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0003-4111-2757
Jean-François BoileauJewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Nathaniel BouganimMcGill University Health Centre, McGill University, Montréal, QC H4A 3J1, Canada.
Christine Brezden-MasleyMarvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.ORCID 0000-0002-4818-318X
Jeffrey Q CaoArthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.
David W CesconPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-1080-0998
Stephen ChiaBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
Scott EdwardsDr. H. Bliss Murphy Cancer Centre, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Anil Abraham JoyCross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.ORCID 0000-0003-4201-8930
Kara LaingDr. H. Bliss Murphy Cancer Centre, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
Nathalie LeVasseurBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-2581-4903
Sandeep SehdevThe Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.ORCID 0000-0001-7434-2263
Christine SimmonsBC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0002-6571-4587
Marc WebsterArthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada.
Mita MannaSaskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada.ORCID 0000-0003-4344-7913
On Behalf Of Patient Advocacy Breast Cancer Canada

Funding

Breast Cancer Canada Scope of work #17
6 · The paper itself

Abstract

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype associated with a poor prognosis when not optimally treated. Over the past year, major advances-including results from DESTINY-Breast05, DESTINY-Breast09, DESTINY-Breast11, PATINA, and long-term APHINITY follow-up-have changed the treatment landscape regarding the place in therapy of antibody-drug conjugates and the optimal sequencing of systemic therapies. These developments prompted the need for updated evidence-informed consensus recommendations to support consistent, high-quality care across Canada. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), comprising clinical-academic oncologists from across Canada and Breast Cancer Canada, updated its 2024 HER2+ recommendations through a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% agreement. This 2025 update incorporates new data in early-stage, metastatic, and central nervous system-involved disease, including revisions to neoadjuvant and adjuvant treatment pathways and expanded guidance on the clinical use of antibody-drug conjugates.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCanadaFemaleHumansNeoplasm MetastasisERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesantibody–drug conjugatebreast cancerHER2+HER2-directed therapyHER2-positiveREAL Alliance

Identifiers

PMID42041719
PMCPMC13115210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.